Patient characteristics in the discovery and validation cohorts
| Variable . | Level . | Discovery . | Validation . |
|---|---|---|---|
| n | 60 | 59 | |
| Median age, y (IQR) | 50.5 (38.3-64.3) | 47.5 (38.0-60.5) | |
| Sex (%) | Female | 27 (45.0) | 20 (33.9) |
| Male | 33 (55.0) | 39 (66.1) | |
| Sokal score (%) | High | 13 (22.8) | 7 (12.7) |
| Intermediate | 19 (33.3) | 19 (34.5) | |
| Low | 25 (43.9) | 29 (52.7) | |
| ELTS score (%) | High | 6 (10.5) | 4 (7.3) |
| Intermediate | 18 (31.6) | 11 (20.0) | |
| Low | 33 (57.9) | 40 (72.7) | |
| BCR::ABL1 transcript type (%) | b2a2 | 26 (43.3) | 21 (35.6) |
| b2a3 | 0 (0.0) | 1 (1.7) | |
| b3a2 | 20 (33.3) | 23 (39.0) | |
| both | 14 (23.3) | 14 (23.7) | |
| EMR status (%) | EMR | 52 (86.7) | 53 (89.8) |
| No EMR | 8 (13.3) | 6 (10.2) | |
| DMR by 5 y (%) | MR4.5 | 38 (63.3) | 37 (62.7) |
| No MR4.5 | 22 (36.7) | 22 (37.3) |
| Variable . | Level . | Discovery . | Validation . |
|---|---|---|---|
| n | 60 | 59 | |
| Median age, y (IQR) | 50.5 (38.3-64.3) | 47.5 (38.0-60.5) | |
| Sex (%) | Female | 27 (45.0) | 20 (33.9) |
| Male | 33 (55.0) | 39 (66.1) | |
| Sokal score (%) | High | 13 (22.8) | 7 (12.7) |
| Intermediate | 19 (33.3) | 19 (34.5) | |
| Low | 25 (43.9) | 29 (52.7) | |
| ELTS score (%) | High | 6 (10.5) | 4 (7.3) |
| Intermediate | 18 (31.6) | 11 (20.0) | |
| Low | 33 (57.9) | 40 (72.7) | |
| BCR::ABL1 transcript type (%) | b2a2 | 26 (43.3) | 21 (35.6) |
| b2a3 | 0 (0.0) | 1 (1.7) | |
| b3a2 | 20 (33.3) | 23 (39.0) | |
| both | 14 (23.3) | 14 (23.7) | |
| EMR status (%) | EMR | 52 (86.7) | 53 (89.8) |
| No EMR | 8 (13.3) | 6 (10.2) | |
| DMR by 5 y (%) | MR4.5 | 38 (63.3) | 37 (62.7) |
| No MR4.5 | 22 (36.7) | 22 (37.3) |
IQR, interquartile range.